What is Adecto Pharmaceuticals?
Adecto Pharmaceuticals is a pre-clinical stage therapeutic company dedicated to developing targeted treatments for aggressive ADAM8-positive cancers. Their innovative strategy includes the creation of a companion diagnostic to precisely identify patients who would benefit most from their therapies. With a foundation built on over 30 years of dedicated research, Adecto Pharmaceuticals aims to significantly impact cancer treatment by halting both primary tumor growth and the spread of metastasis. The company's initial therapeutic focus is on breast cancer, with strategic plans to broaden its application to other oncology indications, potentially benefiting an estimated 2 million patients globally.
How much funding has Adecto Pharmaceuticals raised?
Adecto Pharmaceuticals has raised a total of $48K across 1 funding round:
Debt
$48K
Debt (2021): $48K with participation from PPP
What's next for Adecto Pharmaceuticals?
The substantial expansion capital Adecto Pharmaceuticals has recently acquired positions the company for a critical phase of growth and development. This strategic investment is expected to accelerate the advancement of their pre-clinical pipeline, particularly their targeted therapies for ADAM8-positive cancers and the development of their companion diagnostic. As the company moves towards clinical trials, this financing will be instrumental in scaling operations, expanding their research and development teams, and preparing for potential future funding rounds or commercialization efforts. The focus on breast cancer, with a roadmap for other oncology indications, suggests a long-term vision for broad market impact.
See full Adecto Pharmaceuticals company page
